n Cardiovascular Journal of South Africa - CHARM shows benefits of Atacand(R) for symptomatic heart failure : drug trends in cardiology

Volume 14, Issue 5
  • ISSN : 1680-0745



Extracted from text ... 284 Atacand(r) (candesartan cilexetil) an angiotensin receptor blocker (ARB) is proven to reduce cardiovascular death and hospitalisation in chronic heart failure when given together with conventional therapy. AstraZeneca presented data at the European Society of Cardiology (ESC, Vienna, August 2003) annual meeting demonstrating candesartan cilexetil to reduce both cardiovascular deaths as well as hospital admissions for heart failure across a broad spectrum of patients with chronic heart failure. Importantly, candesartan cilexetil is the first angiotensin receptor blocker (ARB) to increase survival in chronic heart failure patients with left ventricular dysfunction, whether or not they are taking an ACE inhibitor. The CHARM ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error